In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1- methyl-4-phenylpyridinium

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 2, 2000, Pages 329-335

  Staal, Roland G W ^a   Hogan, Kelly A ^a   Liang, Chang Lin ^b   German, Dwight C ^b   Sonsalla, Patricia K ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; MALE; MOUSE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SYNAPSE VESICLE; TRANSPORT KINETICS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; COCAINE; DOPAMINE AGENTS; DOPAMINE UPTAKE INHIBITORS; INDICATORS AND REAGENTS; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICROSCOPY, ELECTRON; NEOSTRIATUM; NEUROPEPTIDES; NEUROTOXINS; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SYNAPTIC VESICLES; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0034012173     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Akera T and Cheng VJK (1977) A simple method for the determination of affinity and binding site concentration in receptor binding studies. Biochim Biophys Acta 470:412-423.
2. Chiba K, Trevor A and Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578.
3. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM and Kopin IJ (1984) Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2.3,6-tetrahydropyridine (MPTP) in rat, guinea pig and monkey. Psychapharmacol Bull 20:548-553.
4. Daniel AJ and Reinhard JF (1988) Energy-driven uptake of the neurotoxin 1-methyl4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 263:5034-5036.
5. Del Zompo M, Piccardi MP, Ruiu S, Quartu M, Gessa GL and Vaccari A (1993) Selective uptake into synaptic dopamine vesicles: Possible involvement in MPTP neurotoxicity. Br J Pharmacol 109:411-414.
6. 3 H]-dopamine accumulation by synaptic vesicles purified from rat striatum: Inhibition by thiocyanate ion. Brain Res 516:155-160.
7. Floor E, leventhal PS, Wang Y, Meng L and Chen WQ (1995) Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurockem 64:689-699.
8. Fuller RW and Steranka LR (1985) Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Res Commun Chem Pathol Pharmacol 48:17-25.
9. Gainetdinov RR, Fumagalli F, Wang Y-M, Jones SR, Levey AI, Miller GW and Caron MG (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973-1978.
10. Giovanni A, Sieber BA, Heikkila RE and Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 257:691-697.
11. Giovanni A, Sieber BA, Heikkila RE and Sonsalla PK (1994a) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 270:1000-1007.
12. Giovanni A, Sonsalla PK and Heikkila RE (1994b) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 270:1008-1014.
13. 3H] GBR 12935 (1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine) to membranes and to solubilized membrane extracts from terminal field regions of mesolimbic, mesocortical and nigrostriata) dopamine pathways. Neuropharmacology 29:1017-1024.
14. Javitch JA, D'Amato RJ, Strittmatter SM and Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by dopamine neurons explains selective toxicity. Prac Natl Acad Sci USA 82:2173-2177.
15. Kilbourn MJ and Frey K (1996) Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and insensitive (CD-1) mouse strains. Eur J Pharmacol 307:227-232.
16. + toxicity encodes a vesicular amine transporter. Cell 70:539-551.
17. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharmacol 36:518-524.
18. 3H]-dihydrotetrabenazine binding in bovine striatal subsynaptic fractions: Enrichment of higher affinity binding in a synaptic vesicle fraction. J Neurochem 50:824-830.
19. Moriyama Y, Amakatsu K and Futai M (1993) Uptake of the neurotoxin, 4-methyl-phenylpyridinium, into chromaffin granules and synaptic vesicles: A proton gradient drives its uptake through monoamine transporter. Arch Biochem Biophys 305:271-277.
20. Nirenberg MJ, Chan J, Liu Y, Edwards RH and Pickel VM (1997) Vesicular monoamine transporter-2: Immunogold localization in striatal axons and terminals. Synapse 26:194-198.
21. Ramsay RR and Singer TP (1986) Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261:7585-7587.
22. Reinhard JF Jr, Carmichael SW and Daniels AJ (1990) Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. J Neurochem 55:311-320.
23. Reinhard JF Jr, Daniels AJ and Humberto Viveros O (1988) Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse: Evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 90:349-353.
24. Reinhard JF Jr, Diliberto EJ, Humberto Viveros O and Daniels AJ (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 84:8160-8164.
25. 3H]GBR 12935: Binding characteristics. Brain Res 540:1-13.
26. Russo SM, Daniels AJ, Humberto Viveros O and Reinhard JF Jr (1994) Differences in the reserpine-sensitive storage in vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurotoxicol Teratol 16:277-281.
27. Sherman D (1986) Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 47:331-339.
28. Sonsalla PK and Nicklas WJ (1992) MPTP and animal models of Parkinson's Disease, in Handbook of Parkinson's Disease (Koller WC ed) pp 319-340, Marcel Dekker, New York.
29. Speciale SG, Liang C-L, Sonsalla PK, Edwards RH and German DC (1998) The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84:1177-1185.
30. Staal RGW and Sonsalla PK (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293:336-342.
31. Tanaka R, Asaga H and Takeda M (1976) Nucleoside triphosphate and cation requirement for dopamine uptake by plain synaptic vesicles isolated from rat cerebrums. Brain Res 115:273-283.
32. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S and Uhl GR (1997) VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943.
33. 3H] dopamine uptake. J Pharmacol Exp Ther 280:1432-1444.
34. Vyas I, Heikkila RE and Nicklas WJ (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 46:1501-1507.
35. Zimanyi I, Lajtha A and Reith MEA (1989) Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Arch Pharmacol 340:626-632.
36. Zuddas A, Fascetti F, Corsini GU and Piccardi MP (1994) In brown Norway rats, MPP' is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: A model of natural resistance to MPTP toxicity. Exp Neural 127:54-61.